natgillin/translations-raw huggingface dataset:
* Contains one or more components that inhibit CYP3A4 and can increase plasma concentrations of medicinal products metabolized by CYP3A4.
* Vsebuje eno ali več sestavin, ki zavira CYP3A4 in lahko zviša plazemsko koncentracijo zdravil, ki se presnavljajo s CYP3A4.
The effect of intensive lipid lowering on major cardiovascular endpoints was not investigated in this study.
Učinek intenzivnega znižanja lipidov na glavne srčnožilne opazovane dogodke v tej študiji ni bil raziskan.
Because of the potential for serious adverse reactions, women taking {PRODUCT NAME} should not breast-feed their infants (see section 4.3).
Zaradi možnosti resnih neželenih učinkov, ženske, ki jemljejo zdravilo {(Lastniško) ime}, ne smejo dojiti svojih otrok (glejte poglavje 4.3).
Each daily dose of atorvastatin is given all at once and may be given at any time of day with or without food.
Dnevni odmerek je treba zaužiti naenkrat, kadarkoli čez dan, s hrano ali brez nje.
• urine tests that are positive for white blood cells
• pozitiven izvid preiskave urina za bele krvne celice.
This was mainly due to a 26% reduction in re-hospitalisation for angina pectoris with evidence of myocardial ischaemia (p=0.018).
Razlog za to je bilo predvsem 26-odstotno zmanjšanje števila ponovnih hospitalizacij zaradi angine pektoris z znaki ishemije miokarda (p = 0,018).
• anorexia (loss of appetite), weight gain, decreases in blood sugar levels (if you have diabetes you should continue careful monitoring of your blood sugar levels)
• anoreksija (izguba apetita), pridobivanje telesne mase, upadanje ravni sladkorja v krvi (če imate sladkorno bolezen, morate še naprej skrbno spremljati raven sladkorja v krvi),
A favourable trend was observed regarding the mortality rate (82 deaths in the placebo group vs. 61 deaths in the atorvastatin group, p=0.0592).
Opažen je bil ugoden trend glede na stopnjo smrtnosti (82 smrti v skupini s placebom, 61 smrti v skupini z atorvastatinom, p = 0,0592).
Overall and cardiovascular mortality were numerically higher in the female patients (38 vs. 30 and 17 vs. 12), but this was not statistically significant.
Celotna umrljivost in srčnožilna umrljivost sta bili številčno večji pri ženskah (38 v primerjavi s 30 in 17 v primerjavi z 12), vendar to ni bilo statistično pomembno.
• hepatitis (liver inflammation)
• hepatitis (vnetje jeter),
Creatine kinase measurement
Merjenje kreatin kinaze
Skin rash with pink-red blotches especially on palms of hands or soles of feet which may blister.
Kožni izpuščaj z rožnatordečimi mozolji zlasti na dlaneh ali na podplatih, kjer lahko nastanejo mehurji.
AMI = acute myocardial infarction; CABG = coronary artery bypass graft; CHD = coronary heart disease; MI = myocardial infarction; PTCA = percutaneous transluminal coronary angioplasty.
AMI = akutni miokardni infarkt; CABG (coronary artery bypass graft) = obvodna operacija koronarne arterije; MI = miokardni infarkt; PTCA (percutaneous transluminal coronary angioplasty) = perkutana transluminalna koronarna angioplastika
1Based on difference in crude events rates occurring over a median follow-up of 3.9 years.
1Na podlagi razlike med okvirnim številom dogodkov v povprečnem obdobju spremljanja 3,9 leta.
Rare reports of congenital anomalies following intrauterine exposure to HMG-CoA reductase inhibitors have been received.
Redko so poročali o prirojenih anomalijah po intrauterini izpostavljenosti zaviralcem HMG-CoA reduktaze.
− If you have any further questions, ask your doctor or pharmacist.
- Če imate dodatna vprašanja, se posvetujte z zdravnikom ali s farmacevtom.
If you experience any of the following serious side effects, stop taking your tablets and tell your doctor immediately or go to the nearest hospital accident and emergency department.
Če izkusite katerega izmed naslednjih resnih neželenih učinkov, prenehajte z jemanjem zdravila in nemudoma obvestite svojega zdravnika ali pojdite v najbližjo bolnišnico na nezgodni oddelek ali oddelek za nujno medicinsko pomoč.
− Serious allergic reaction which causes swelling of the face, tongue and throat that can cause great difficulty in breathing.
- Huda alergijska reakcija, ki povzroči oteklost obraza, jezika in sapnika, ki lahko povzroči velike težave pri dihanju.
Atorvastatin increased mean HDL-C by 2.9% (pravastatin: +5.6%, p=NS).
Atorvastatin je zvišal povprečni holesterol HDL za 2,9 % (pravastatin: +5,6 %, p = NZ).
Interaction studies evaluating the effects of amiodarone or verapamil on atorvastatin have not been conducted.
Študij o medsebojnem delovanju zdravil, ki bi ovrednotile učinke amiodarona ali verapamila na atorvastatin, ni.
The response is maintained during chronic therapy.
Odziv se med kroničnim zdravljenjem ohrani.
In cases where co-administration of these medicinal products with atorvastatin is necessary, the benefit and the risk of concurrent treatment should be carefully considered.
Če je potrebna sočasna uporaba teh zdravil z atorvastatinom, je treba natančno pretehtati koristi in tveganja takšnega sočasnega zdravljenja.
− If symptoms resolve and CK levels return to normal, then re-introduction of atorvastatin or introduction of an alternative statin may be considered at the lowest dose and with close monitoring.
- Če simptomi minejo in se CK normalizira, pretehtamo možnost ponovne uvedbe atorvastatina ali uvedbe kakšnega drugega statina v najmanjšem odmerku in ob natančnem nadzoru.
Maternal treatment with atorvastatin may reduce the fetal levels of mevalonate which is a precursor of cholesterol biosynthesis.
Zdravljenje nosečnic z atorvastatinom lahko plodu zmanjša raven mevalonata, ki je predhodnik biosinteze holesterola.
Clinical Recommendation
Klinično priporočilo
The safety profile of atorvastatin in the MIRACL study was consistent with what is described in section
Varnostni profil atorvastatina je bil v študiji MIRACL skladen z navedbami v poglavju 4.8.
Do not take {PRODUCT NAME} if you are pregnant, or if you are trying to become pregnant.
Ne jemljite zdravila {(Lastniško) ime}, če ste noseči ali če skušate zanositi.
After oral administration, atorvastatin film-coated tablets are 95% to 99% bioavailable compared to the oral solution.
Po peroralni uporabi filmsko obloženih tablet atorvastatina je njegova biološka uporabnost v primerjavi z raztopino od 95 do 99 %.
In rats, there is evidence of placental transfer.
Pri podganah obstajajo dokazi o prehodu skozi placento.
Poland, Romania, Slovakia, Slovenia
Romunija, Slovaška, Slovenija
− Muscle weakness, tenderness or pain and particularly, if at the same time, you feel unwell or have a high temperature it may be caused by an abnormal muscle breakdown which can be life-threatening and lead to kidney problems.
- Mišična šibkost, občutljivost na dotik ali bolečina, in še posebej, če to spremljata slabo počutje in vročina, lahko nastane zaradi nenormalne razgradnje mišic, ki je lahko življenjsko nevarno stanje in povzroča ledvične težave.
These differences were of no clinical significance, resulting in no clinically significant differences in lipid effects among men and women.
Razlike niso klinično pomembne in učinek zdravila na lipide se med moškimi in ženskami klinično ne razlikuje.
• an allergic reaction - symptoms may include sudden wheezing and chest pain or tightness, swelling of the eyelids, face, lips, mouth, tongue or throat, difficulty breathing, collapse
• alergijska reakcija - simptomi lahko vključujejo nenadno sopenje in bolečino ali prsno stisko, otekanje vek, obraza, ustnic, jezika in žrela, oteženo dihanje in kolaps
Do not take {PRODUCT NAME} if you are able to become pregnant unless you use reliable contraceptive measures.
Ne jemljite zdravila {(Lastniško) ime}, če obstaja možnost, da zanosite, razen če uporabljate učinkovito kontracepcijsko zaščito.
− If you experience problems with unexpected or unusual bleeding or bruising, this may be suggestive of a liver complaint.
- Če pride do težav z nepričakovanim ali nenavadnim krvavenjem ali podplutbami, lahko to kaže na težave z jetri.
If co-administration cannot be avoided, simultaneous coadministration of atorvastatin with rifampin is recommended, with clinical monitoring.
Če se sočasni uporabi ne da izogniti, je pri sočasni uporabi atorvastatina z rifampinom priporočeno klinično spremljanje.
Ciclosporin 5.2 mg/kg/day, stable dose
Ciklosporin 5,2 mg/kg/dan, stalni odmerek
Pharmacotherapeutic group: Lipid modifying agents, HMG-CoA-reductase inhibitors, ATC code: C10AA05
Farmakoterapevtska skupina: zdravila, ki spreminjajo raven lipidov, zaviralci HMG CoA reduktaze, oznaka ATC: C10AA05
[See Annex I - To be completed nationally] {Name and Address} <{tel}> <{fax}> <{e-mail}>
[Glejte Dodatek I - Izpolni država članica] {Ime in naslov} <{tel)> <{fax}> <{e-mail}>
Large quantities of grapefruit juice (over 1.2 l daily for 5 days) increased AUC of atorvastatin 2.5 fold and AUC of active (atorvastatin and metabolites).
Velike količine grenivkinega soka (več kot 1,2 l v 5 dneh) so povečale AUC atorvastatina 2,5-krat in AUC aktivnosti (atorvastatina in presnovkov).
Developmental safety data in this population have not been evaluated.
Podatkov o varnosti za otrokov razvoj ni.
Appropriate clinical monitoring of these patients is recommended.
Priporočljivo je ustrezno klinično spremljanje teh bolnikov.
Animal studies have shown toxicity to reproduction (see section 5.3).
Študije na živalih so pokazale vpliv na sposobnost razmnoževanja (glejte poglavje 5.3)
Atorvastatin was negative for mutagenic and clastogenic potential in a battery of 4 in vitro tests and 1 in vivo assay.
Atorvastatin ni pokazal mutagenega ali klastogenega potenciala v naboru 4 testov in vitro in 1 preskusu in vivo.
Check with your doctor or pharmacist before taking {PRODUCT NAME} − if you have severe respiratory failure.
Preden vzamete zdravilo {(Lastniško) ime} , se posvetujte z zdravnikom ali s farmacevtom - če imate hude težave z dihanjem
However, atorvastatin does not appear to undergo significant enterohepatic recirculation.
Kot kaže, atorvastatin nima pomembne enterohepatične recirkulacije.
Patients were treated with either atorvastatin 10 mg daily (n=1,428) or placebo (n=1,410) for a median follow-up of 3.9 years.
Bolnike so zdravili bodisi z atorvastatinom 10 mg na dan (n = 1.428), bodisi s placebom (n = 1.410); povprečno spremljanje je trajalo 3,9 leta.
Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.
Ko smo dokumentirali stabilen protrombinski čas, lahko protrombinski čas spremljamo v časovnih presledkih, ki so tudi sicer priporočeni za bolnike, zdravljene s kumarinskimi antikoagulanti.
Higher doses may be necessary in order to attain (LDL-) cholesterol levels according to current guidelines.
Za doseganje ravni holesterola LDL, kakršne priporočajo trenutne smernice, bodo morda potrebni višji odmerki.
Gender: Concentrations of atorvastatin and its active metabolites in women differ from those in men (Women: approx. 20% higher for Cmax and approx. 10% lower for AUC).
Spol: Koncentracija atorvastatina in njegovih aktivnih presnovkov je pri ženskah drugačna kot pri moških (Cmax je pri ženskah približno 20 % večja, AUC pa 10 % manjša) kot pri moških.
Antacid suspension of magnesium and aluminium hydroxides, 30 mL QID, 2 weeks
Antacidna suspenzija magnezijevih in aluminijevih hidroksidov, 30 ml štirikrat na dan, 2 tedna
In rats, plasma concentrations of atorvastatin and its active metabolites are similar to those in milk (see section 5.3).
Pri podganah je bila koncentracija atorvastatina in njegovih aktivnih presnovkov v plazmi podobna kot v mleku (glejte poglavje 4.3).
OTHER SPECIAL WARNING(S), IF NECESSARY [To be completed nationally]
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA [Izpolni država članica]
Presenting features can include dyspnoea, non-productive cough and deterioration in general health (fatigue, weight loss and fever).
Med značilnostmi, ki se lahko pojavijo, so dispneja, neproduktivni kašelj in poslabšanje splošnega zdravstvenega stanja (utrujenost, zmanjšanje telesne mase in zvišana telesna temperatura).
Renal insufficiency: Renal disease has no influence on the plasma concentrations or lipid effects of atorvastatin and its active metabolites.
Ledvična insuficienca: Bolezen ledvic ne vpliva niti na koncentracijo atorvastatina in njegovih aktivnih presnovkov v plazmi niti na njihov učinek na lipide.
Patients who develop increased transaminase levels should be monitored until the abnormality(ies) resolve.
Bolnike z zvišanimi vrednostmi transaminaz je treba nadzorovati, dokler nenormalnost(i) ne izgine(jo).
* Co-administration of multiple doses of atorvastatin and phenazone showed little or no detectable effect in the clearance of phenazone.
* Sočasna uporaba večkratnih odmerkov atorvastatina in fenazona je na očistek fenazona vplivala malo ali nič.
Reductions in total-C, LDL-C, and apolipoprotein B have been proven to reduce risk for cardiovascular events and cardiovascular mortality.
Znižanje celotnega holesterola, holesterola LDL in apolipoproteina B dokazano zmanjša tveganje za srčnožilne zaplete in umrljivost zaradi bolezni srca in ožilja.
Should an increase in transaminases of greater than 3 times the upper limit of normal (ULN) persist, reduction of dose or withdrawal of {PRODUCT NAME} is recommended (see section 4.8).
Če zvišanje transaminaz, ki presega 3-kratno zgornjo normalno mejo (ZNM), traja, je odmerek zdravila {(Lastniško) ime} priporočljivo zmanjšati ali zdravilo ukiniti (glejte poglavje 4.8).
Specific treatment is not available for {PRODUCT NAME} overdose.
Specifičnega zdravljenja za prevelik odmerek zdravila {(Lastniško) ime} ni.
Dose (mg)
Zdravilo/odmerek (mg)
SLOC1B1 polymorphism: Hepatic uptake of all HMG-CoA reductase inhibitors including atorvastatin, involves the OATP1B1 transporter.
Polimorfizem SLOC1B1: Jetrni privzem vseh zaviralcev reduktaze HMG-CoA, vključno z atorvastatinom, vključuje prenašalec OATP1B1.
In patients with SLCO1B1 polymorphism there is a risk of increased exposure of atorvastatin, which may lead to an increased risk of rhabdomyolysis (see section 4.4).
Pri bolnikih s polimorfizmom SLOCIB1 obstaja tveganje za povečano izpostavljenost atorvastatinu, ki lahko vodi do povečanega tveganja za rabdomiolizo (glejte poglavje 4.4).
The effect of inhibition of hepatic uptake transporters on atorvastatin concentrations in hepatocytes is unknown.
Učinek zaviranja prenašalca jetrnega privzema na koncentracije atorvastatina v hepatocitih ni znan.
The risk of muscle related side effects e.g rhabdomyolysis is known to increase when certain medicines are taken at the same time (see Section 2 “Taking other medicines”).
Tveganje za neželene učinke, povezane z mišicami (npr. rabdomiolizo), se poveča, če sočasno jemljete nekatera druga zdravila (glejte poglavje 2 "Uporaba drugih zdravil").
The risk of myopathy may also be increased with the concomitant use of gemfibrozil and other fibric acid derivates, erythromycin, niacin and ezetimibe.
Tveganje za miopatijo lahko poveča tudi sočasna uporaba gemfibrozila in drugih derivatov fibrinske kisline, eritromicina, niacina in ezetimiba.
Liver function tests should be performed and serum CK levels should be monitored.
Narediti je treba laboratorijske preiskave jetrne funkcije in nadzorovati raven CK v serumu.
When patients are receiving medicinal products that increase the plasma concentration of atorvastatin, a lower maximum dose of atorvastatin is recommended.
Če bolniki dobivajo zdravila, ki povečujejo koncentracijo atorvastatina v plazmi, je priporočljivo uporabiti manjši največji odmerek atorvastatina.
No controlled clinical trials with atorvastatin have been conducted in pregnant women.
Opravljenja ni bila nobena nadzorovana klinična študija nosečnic.
The following adverse events have been reported with some statins:
Pri uporabi nekaterih statinov so poročali o naslednjih neželenih učinkih:
Although only very rare cases of clinically significant anticoagulant interactions have been reported, prothrombin time should be determined before starting atorvastatin in patients taking coumarin anticoagulants and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.
Čeprav je bilo v le izjemno redkih primerih opaženo klinično pomembno antikoagulantno medsebojno delovanje, je potrebno pred začetkom uporabe atorvastatina bolnikom, ki jemljejo kumarinske antikoagulante, izmeriti protrombinski čas, nato pa to dovolj pogosto ponoviti še v začetnih fazah zdravljenja, da se prepričamo, da ni prišlo do pomembne spremembe protrombinskega časa.
The risk might also be increased at concomitant administration of atorvastatin with other medicinal products that have a potential to induce myopathy, such as fibric acid derivates and ezetimibe (see section 4.4).
Tveganje lahko poveča tudi sočasna uporaba atorvastatina z drugimi zdravili, ki imajo potencial za povzročanje miopatije, denimo derivatov fibrinske kisline in ezetimiba (glejte poglavje 4.4).
There was significant treatment interaction by antihypertensive baseline therapy.
Opazili so pomembno interakcijo z zdravljenjem glede na izhodiščno antihipertenzivno terapijo.
If possible, alternative (non-interacting) therapies should be considered instead of these medicinal products.
Če je mogoče, je treba namesto o zdravljenju s temi zdravili razmisliti o drugih terapijah, pri katerih ni medsebojnih delovanj.
It is not known whether atorvastatin or its metabolites are excreted in human milk.
Ni znano, ali se atorvastatin ali njegovi presnovki izločajo pri ljudeh v materino mleko.
• Breathing problems including persistent cough and/or shortness of breath or fever
• težave z dihanjem, vključno z nenehnim kašljanjem in/ali zasoplost ali zvišana telesna temperatura.
Due to extensive atorvastatin binding to plasma proteins, haemodialysis is not expected to significantly enhance atorvastatin clearance.
Ker se atorvastatin v veliki meri veže na beljakovine v plazmi, ni pričakovati, da bi hemodializa pomembno zvečala njegov očistek.
Elevated serum creatine kinase (CK) levels greater than 3 times upper limit of normal occurred in 2.5% of patients on {PRODUCT NAME}, similar to other HMG-CoA reductase inhibitors in clinical trials.
Zvišanje kreatin kinaze (CK), ki je presegalo 3-kratno ZNM, se je pojavilo pri 2,5% bolnikov, ki so jemali zdravilo {(Lastniško) ime}, kar je podobno kot v kliničnih raziskavah z drugimi zaviralci HMG CoA reduktaze.
Do not use any tools or machines if your ability to use them is affected by this medicine.
Vendar pa ne vozite avtomobila ali upravljajte orodij ali strojev, če to zdravilo vpliva na vašo sposobnost za te dejavnosti.
Therefore, this SPC, labelling and package leaflet may not necessarily represent the current text.
Tako ta povzetek glavnih značilnosti zdravila, označevanja in navodilo za uporabo morda ne odražajo trenutnega besedila.
Common: headache.
Pogosto: glavobol
Hepatic impairment {PRODUCT NAME} should be used with caution in patients with hepatic impairment (see sections 4.4 and 5.2).
Pri bolnikih z jetrno okvaro je treba zdravilo {(Lastniško) ime} uporabljati previdno (glejte poglavji 4.4 in 5.2).
• having nightmares, insomnia
• nočne more, nespečnost,
Rare: myopathy, myositis, rhabdomyolysis, tendonopathy, sometimes complicated by rupture.
Redko: miopatija, miozitis, rabdomioliza, tendinopatija, občasno z zapletom pretrganje tetive
There was no evidence of a difference in the treatment effect by patient's gender, age, or baseline LDL-C level.
Ni bilo dokazov, da bi se učinek zdravljenja razlikoval glede na spol bolnikov, njihovo starost ali izhodiščno koncentracijo holesterola LDL.
If CK levels are significantly elevated at baseline (> 5 times ULN), levels should be remeasured within 5 to 7 days later to confirm the results.
Če je vrednost CK izhodiščno zelo velika (> 5-kratna ZNM), je treba CK za potrditev izvida ponovno izmeriti čez 5 do 7 dni.
Patients were treated with anti-hypertensive therapy (either amlodipine or atenolol-based regimen) and either atorvastatin 10 mg daily (n=5,168) or placebo (n=5,137).
Bolnike so zdravili z antihipertenzivno terapijo (program na podlagi amlodipina ali atenolola) ter bodisi z 10 mg atorvastatina na dan (n = 5.168), bodisi s placebom (n = 5.137).
The mean LDL-C was 73 mg/dL (1.9 mmol/L) during treatment with atorvastatin and 129 mg/dL (3.3 mmol/L) during treatment with placebo.
Povprečni holesterol LDL je bil 1,9 mmol/l (73 mg/dl) med zdravljenjem z atorvastatinom in 3,3 mmol/l (129 mg/dl) med zdravljenjem s placebom.
Atorvastatin iiss effective in reducing LDL-C in patients with homozygous familial hypercholesterolaemia, a population that has not usually responded to lipid-lowering medicinal products.
Atorvastatin učinkovito zniža holesterol LDL pri bolnikih s homozigotno familiarno hiperholesterolemijo, se pravi v populaciji, ki se ponavadi ne odzove na zdravljenje s hipolipemičnimi zdravili.
Before starting treatment, your doctor will place you on a low-cholesterol diet, which you should maintain also during therapy with {PRODUCT NAME}.
Pred začetkom zdravljenja vam bo zdravnik predpisal prehrano z nizko vsebnostjo holesterola, ki se je morate držati tudi med zdravljenjem z zdravilom {(Lastniško) ime}.
Total mortality and cardiovascular mortality were not significantly reduced (185 vs. 212 events, p=0.17 and 74 vs. 82 events, p=0.51).
Celotna umrljivost in srčnožilna umrljivost se nista pomembno zmanjšali (185 dogodkov v primerjavi z 212, p=0,17, in 74 dogodkov v primerjavi z 82, p=0,51).
Atorvastatin was not found to be carcinogenic in rats, but high doses in mice (resulting in 6-11 fold the AUC0-24h reached in humans at the highest recommended dose) showed hepatocellular adenomas in males and hepatocellular carcinomas in females.
Atorvastatin za podgane ni bil karcinogen, vendar pa se je pri visokih odmerkih pri miših (na podlagi AUC(0-24) od 6- do 11-krat višja kot pri najvišjem odmerku za človeka) nastal hepatocelularni adenom pri samcih in hepatocelularni karcinom pri samicah.
Exceptional cases of interstitial lung disease have been reported with some statins, especially with long term therapy (see section 4.8).
Med uporabo nekaterih statinov so bili opisani izjemni primeri intersticijske bolezni pljuč, zlasti med dolgotrajnim zdravljenjem (glejte poglavje 4.8).
− This medicine has been prescribed for you.
- To zdravilo je bilo predpisano vam osebno in ga ne smete dajati drugim.
{PRODUCT NAME} is used to lower lipids known as cholesterol and triglycerides in the blood when a low fat diet and life style changes on their own have failed.
Zdravilo {(Lastniško) ime} se uporablja za znižanje zvišane ravni holesterola in trigliceridov v krvi, kadar prehrana z malo maščob in spremembe življenjskega stila niso dovolj učinkovite.
Approximately 70% of circulating inhibitory activity for HMG-CoA reductase is attributed to active metabolites.
Približno 70 % zaviralnega delovanja na HMG CoA reduktazo v obtoku pripisujejo aktivnim presnovkom.
The effect of atorvastatin on fatal and non-fatal coronary heart disease was assessed in a randomized, double-blind, placebo-controlled study, the Anglo-Scandinavian Cardiac Outcomes Trial Lipid Lowering Arm (ASCOT-LLA).
Učinek atorvastatina na koronarno srčno bolezen s smrtnim izidom in brez njega so ocenili v randomizirani, dvojno slepi, s placebom kontrolirani študiji ASCOT-LLA (Anglo-Scandinavian Cardiac Outcomes Trial Lipid Lowering Arm).
Potent CYP3A4 inhibitors have been shown to lead to markedly increased concentrations of atorvastatin (see Table 1 and specific information below).
Ugotovili so, da močni zaviralci CYP3A4 povzročajo znatno povečane koncentracije atorvastatina (glejte Preglednico 1 in specifične informacije o tem spodaj).
Patients were 60% male, 21-92 years of age (average age 63 years), and had an average baseline LDL of 133 mg/dL (3.4 mmol/L).
Med bolniki je bilo 60 % moških; starost skupine je bila od 21 do 92 let (povprečje: 63 let) in povprečni izhodiščni LDL je bil 3,4 mmol/l (133 mg/dl).
Atorvastatin is metabolized by cytochrome P450 3A4 to ortho- and parahydroxylated derivatives and various beta-oxidation products.
Atorvastatin se s citokromom P450 3A4 presnavlja v orto- in parahidroksilirane derivate in različne betaoksidacijske produkte.